Conditions: Uremic Pruritus Pruritus
Keywords: Uremic Pruritus Itch Chronic Itch Nalbuphine
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 167
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.

Detailed description:

Arms:
arm 1: nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.

Interventions: intervention 1: nalbuphine HCl ER
Intervention descriptions: intervention 1: nalbuphine HCl ER

Protocol document: